Journal of the National Cancer Institute Advance Access originally published online on November 11, 2008
JNCI Journal of the National Cancer Institute 2008 100(22):1571-1573; doi:10.1093/jnci/djn422
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2008.
NEWS |
Preventive Services Task Force Recommends Against PSA Screening After Age 75
| The first 150 words of the full text of this article appear below. |
For years, physicians and their patients have decided, on an individual basis, whether or not to use a prostate-specific antigen (PSA) screening test, which can detect not only life-threatening prostate cancer but also many cancers that may never pose a danger. No clear evidence exists for whether the test provides more benefit or harm, given the aggressive treatments that often follow a positive cancer diagnosis, and so patients and physicians face a difficult choice about whether to use the test.
Without definitive data, the U.S. Preventive Services Task Force (USPSTF), part of the federal Agency for Healthcare Research and Quality, issued guidelines in 1996 and again in 2002 that said it cannot recommend for or against PSA testing. Many other organizations that provide guidance to physicians ordering PSA tests—such as the American Cancer Society, the American College of Physicians, and the American Academy of Family Physicians (AAFP)—also adopted this position.
Different Viewpoints, Limited Data
"Temper the Guideline as Needed"
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. P. Browman, T. Berrang, and S. Smith Prognostic Tools for Cancer Survival: A Secondary Role for Quality-of-Life Measurement J. Clin. Oncol., June 20, 2009; 27(18): 2902 - 2904. [Full Text] [PDF]
|
|